The effect of a gastric bypass on the pharmacokinetics of citalopram

Conditions: Depression
Gastric Bypass
10027946
10017998

Registration Number: NL-OMON55680

Lead Sponsor: Maasstadziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 19

Inclusion Criteria

- Age of 18 years and older
- The patient uses citalopram daily
- The patient is prescribed citalopram at least 2 month before included in the
studie, and uses the same dose for at least one week before bloodsampling
- The patient is on the waitinglist for a primairy Roux- and Y gastric bypass
- The patient is a patient in the Maasstad ziekenhuis or the Franciscus
Gasthuis en Vlietland
- The patient participates voluntary in the study
- The patient has read and understands the information letter and has signed
the consent form

Exclusion Criteria

- Persons who have previously undergone a bariatric procedure
- Persons with an impaired liver and/or kidney function (ALAT> 80 U / l; gamma
GT> 100 U / L; MDRD <50 ml / min)
- Women who are pregnant or are breastfeeding
- Patients who are incompetent
- The participant is on the waiting list for a mini bypass, gastric band,
gastric sleeve or biliopancreatic diversion

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>AUC (area under serum concentration-time curve) of citalopram three months<br /><br>after surgery compared to baseline at one month before the surgery.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The following pharmacokinetic parameters of citalopram at one and three months<br /><br>postoperative compared to baseline at one month prior to surgery.<br /><br>- C max (maximal serum concentration) of citalopram<br /><br>- T max (maximal serum concentration) of citalopram<br /><br>- T1/2 (half-life) of citalopram<br /><br>- Trough levels (serum level at time t = 0) of citalopram</p><br>